Therapeutic Solutions International (TSOI) 10-K 7 Jun 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Jun. 07, 2017	Jun. 30, 2016
Document and Entity Information:
Entity Registrant Name	THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Trading Symbol	tsoi
Amendment Flag	false
Entity Central Index Key	1,419,051
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		777,251,000
Entity Public Float			$ 1,107,627
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 21,910	$ 2,183
Accounts receivable, net		2,184
Inventory	36,435	29,675
Prepaid expenses and other current assets	14,304	213,446
Total current assets	72,649	247,488
Other assets	32,226	12,476
Total assets	104,875	259,964
Current liabilities:
Accounts payable	327,592	277,342
Accrued expenses and other current liabilities	135,164	4,412
Notes payable-related parties, current portion	221,451	207,238
Total current liabilities	684,207	488,992
Notes payable- related parties, less current portion	75,500
Shareholders' Deficit:
Preferred stock, $ 0.001 par value; 5,000,000 shares authorized	0
Common stock, $ 0.001 par value; 990,000,000 shares authorized; 740,251,000 and 541,000,000 shares issued and outstanding at December 31, 2016 and 2015, respectively.	740,251	541,000
Additional paid-in capital	2,878,111	2,440,709
Accumulated deficit	(4,273,194)	(3,210,737)
Total shareholders' deficit	(654,832)	(229,028)
Total liabilities and shareholders' deficit	$ 104,875	$ 259,964

Consolidated Balance Sheets Par

Consolidated Balance Sheets Parentheticals - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Parentheticals
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	5,000,000	5,000,000
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	990,000,000	990,000,000
Common Stock, shares issued	740,251,000	541,000,000
Common Stock, shares outstanding	740,251,000	541,000,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenue
Net Sales	$ 5,009	$ 1,911
Cost of Goods Sold	1,606	3,193
Gross Profit	3,403	(1,282)
Operating expenses:
General and administrative	120,625	69,487
Salaries, wages, and related costs	355,244	266,286
Selling expenses	1,508	3,894
Consulting fees	356,250	185,700
Legal and professional fees	200,957	40,420
Research and development	10,990
Total operating expenses	1,045,574	565,787
Loss from operations	(1,042,171)	(567,069)
Other income (expense):
Interest expense	(20,286)	(5,550)
Total other income (expense)	(20,286)	(5,550)
Net loss from continuing operations	(1,062,457)	(572,619)
Net loss from discontinued operations		(13,822)
Net loss	$ (1,062,457)	$ (586,441)
Net loss per share - basic and diluted	$ 0	$ 0
Weighted average shares outstanding - basic and diluted	668,115,789	461,967,123

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Deficit - USD ($)	Common Stock Shares	Common Stock Amount	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Jan. 01, 2015	400,000,000	400,000	2,093,009	(2,624,296)	(131,287)
Common stock issued for services	60,000,000	60,000	226,200		286,200
Common stock issued	81,000,000	81,000	121,500		202,500
Net Loss				$ (586,441)	$ (586,441)
Balance. at Dec. 31, 2015	541,000,000	541,000	2,440,709	(3,210,737)	(229,028)
Common stock issued for services	68,500,000	68,500	219,800		288,300
Common stock issued in exchange for a license agreement	5,451,000	5,451	10,902		16,353
Common stock issued	125,300,000	125,300	206,700		332,000
Net Loss				$ (1,062,457)	$ (1,062,457)
Balance at Dec. 31, 2016	740,251,000	740,251	2,878,111	(4,273,194)	(654,832)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities
Net loss	$ (1,062,457)	$ (586,441)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation to consultants	$ 288,300	286,200
Shares issued for license agreement	16,353
Accrued interest, notes payable - related parties	$ 16,244	1,147
Changes in operating assets and liabilities:
Inventory	(6,759)	(29,675)
Accounts receivable	2,184	(2,184)
Prepaid expenses and other current assets	199,142	(74,428)
Other assets	(19,750)	(15)
Accounts payable	50,250	(13,212)
Accrued expenses and other current liabilities	130,752	(287)
Cash used in operating activities-continuing operations	(385,741)	(418,895)
Cash provided by operating activities-discontinued operations		46,844
Net cash used in operating activities	(385,741)	(372,051)
Cash flows from financing activities
Proceeds from issuance of common stock	332,000	202,500
Proceeds from notes payable - related parties	76,000	168,840
Repayments of notes payable - related parties	(2,532)
Net cash provided by financing activities	405,468	371,340
Net increase (decrease) in cash	19,727	(711)
Cash at beginning of period	21,910	2,183
Cash at end of period	21,910	2,183
Supplemental Cash Flow Information:
Cash paid for interest	4,040	3,213
Cash paid for income taxes	$ 800	$ 800

Nature of Business

Nature of Business	12 Months Ended
	Dec. 31, 2016
Nature of Business
Nature of Operations	Note 1 – Nature of Business Therapeutic Solutions International, Inc. (“TSI” or the “Company”) was organized August 6, 2007 under the name Friendly Auto Dealers, Inc., under the laws of the State of Nevada. In the first quarter of 2011 the Company changed its name from Friendly Auto Dealers, Inc. to Therapeutic Solutions International, Inc., and acquired Splint Decisions, Inc., a California corporation. Currently the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. Activating one’s immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions. Nutraceutical Division – TSI has been producing high quality nutraceuticals. Its flagship product, ProJuvenol ® ® TSI has experienced recurring losses over the past years which have resulted in accumulated deficits of approximately $4,273 thousand and a working capital deficit of approximately $612 thousand. These conditions raise significant doubt about the Company’s ability to continue as a going concern within one year after the financial statement issuance date. The Company’s ability to continue as a going concern is contingent upon its ability to secure additional financing, increase sales of its products and attain profitable operations. It is the intent of management to continue to raise additional capital. However, there can be no assurance that the Company will be able to secure such additional funds or obtain such on terms satisfactory to the Company, if at all. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Significant Accounting Policies:
Significant Accounting Policies	Note 2 – Significant Accounting Policies Use of Estimates Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates. Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Company’s net loss. Net Loss Per Share Basic net loss per share is calculated based on the weighted-average number of common shares outstanding. Diluted net loss per share is calculated using the weighted-average number of common shares outstanding plus common stock equivalents. Common stock equivalents are excluded from the calculation of diluted net loss per share when their effect is anti-dilutive. As of December 31, 2016 and 2015, common stock equivalents were not material. Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with Accounting Standards Codification (“ASC”) Topic 350 “Intangibles – Goodwill and Other.” Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. Income Taxes The Company accounts for income taxes under ASC 740 "Income Taxes," which codified SFAS 109, "Accounting for Income Taxes" and FIN 48 “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to Stock-Based Compensation Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. Recent Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 will be effective for the Company in the first quarter of 2019 and will be adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company is currently evaluating the impact of this standard on its consolidated financial statements. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The new standard requires management to assess, at each annual and interim reporting period, an entity’s ability to continue as a going concern within one year after the date that the financial statements are issued and to provide related footnote disclosures. ASU 2014-15 is effective for the Company for the year ending December 31, 2016. Based on its adoption of ASU 2014-15, management determined that there is substantial doubt regarding the company’s ability to continue as a growing concern within one year after the issuance of the financial statements (see Note 1). In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The new standard is based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 will be effective for the Company in the first quarter of 2018 and allows for full retrospective or a modified retrospective adoption approach. The adoption of this standard is not expected to have a material impact on the Company’s financial position or results of operations

Restricted Cash

Restricted Cash	12 Months Ended
	Dec. 31, 2016
Restricted Cash:
Restricted Cash	Note 3 – Restricted Cash Other non-current asset is a $10,000 certificate of deposit with an annual interest rate of 0.6%. This certificate matures on June 17, 2017, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011.

Fixed assets

Fixed assets	12 Months Ended
	Dec. 31, 2016
Fixed assets
Fixed assets	Note 4 – Fixed assets Fixed assets consist of the following: December 31, 2016 December 31, 2015 Computer Hardware $ 10,747 $ 10,747 Office Furniture and Equipment 3,639 3,639 Shipping and Other Equipment 1,575 1,575 Total 15,961 15,961 Accumulated Depreciation (15,961) (15,961) Property and Equipment, net $ - $ -

Notes Payable-related party

Notes Payable-related party	12 Months Ended
	Dec. 31, 2016
Notes Payable-related party:
Notes Payable-related party	Note 5 – Notes payable-related parties Notes payable-related parties consist of: December 31, December 31, 2016 2015 Note payable – Scientific Advisory Board Member, unsecured, including interest at 10% per annum, with a maturity date of December 31, 2017 $ 14,721 $ 13,574 Three notes payable – Chief Executive Officer, unsecured, including interest at 8%, 10% and 10% per annum, respectively, with maturity dates of December 31, 2017. 120,330 113,664 Note payable – Chief Financial Officer, unsecured, including interest at 8% per annum, with a maturity date of December 31, 2017. 86,400 80,000 221,451 207,238 Note payable – Business Advisory Board Member, unsecured, including interest at 8% per annum, convertible into common stock at $.005, with a maturity date of May 29, 2018. 75,500 - $ 296,951 $ 207,238

Equity

Equity	12 Months Ended
	Dec. 31, 2016
Equity
Equity	Note 6 – Equity Preferred Stock The Company is authorized to issue 5,000,000 shares of $.001 par value preferred stock. The Company has not issued any preferred stock. Common Stock During the years ended December 31, 2016 and 2015, the Company issued common stock, in several separate transactions, in exchange for various third party services. The shares issued were valued by the Company at their estimated fair market value.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2016
Related Party Transactions:
Related Party Transactions	Note 7 – Related Party Transactions As of December 31, 2016, the Company accrued officers salary of $130,100 as of December 31, 2016. On January 22, 2016, we issued 2,500,000 shares of common stock, valued at $.0035 per share to a director of the Company for services. On February 26, 2016, we issued 1,000,000 shares of common stock, valued at $.0025 per share to a director of the Company for services. On March 7, 2016, we issued 10,000,000 shares of common stock, valued at $.0025 per share to a director of the Company for services. On March 21, 2016, we issued 100,000,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On September 16, 2016, we issued 12,500,000 shares of common stock, valued at $.004 per share, for an investment in the Company’s Private Placement. On October 18, 2 016, we issued 40,000,000 shares valued at $.0045 to the officers and directors of the Company for services. On March 21, 2016, we issued 100,800,000 shares of common stock, valued at $.0025 per share, for an investment in the Company’s Private Placement. On November 11, 2016, we issued a six month convertible note in the amount of $75,000 with an annual interest rate of 8% to a related party.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Taxes
Income Tax Disclosure	Note 8 – Income Taxes The Company has net operating losses carried forward of approximately $3.3 million and $2.3 million as of December 31, 2016 and 2015, respectively, available to offset taxable income in future years which expire beginning in fiscal 2031. The Company is subject to United States federal and state income taxes at an approximate rate of 45%. The reconciliation of the provision for income taxes at the United States federal statutory rate compared to the Company’s income tax expense as reported is as follows: December 31, 2016 December 31, 2015 Expected income tax at statutory rate $ (360,963) $ (263,898) Permanent differences 1,437 88,616 Change in valuation allowance 359,526 175,282 Provision for income taxes $ – $ – The significant components of deferred income tax assets and liabilities at December 31, 2016 and 2015 are as follows: December 31, 2016 December 31, 2015 Net operating loss carry-forward $ 1,262,691 $ 1,021,679 Valuation allowance (1,262,691) (1,021,679) Net deferred income tax asset $ – $ – The valuation allowance has been established to offset the Companys net deferred tax assets, as realization of such assets is not considered to be more likely than not due to Companys history of losses and uncertainties regarding the Companys ability to generate future taxable income sufficient to realize the benefit of these deferred tax assets. Pursuant to Section 382 of the Internal Revenue Code (the “Code”), annual use of the Companys NOL carryforwards may be limited in the event a cumulative change in ownership of 50% of certain shareholders occurs within a three year period. An ownership change may limit the amount of NOL carryforwards that can be utilized annually to offset future taxable income and tax. In general, an “ownership change” as defined by Section 382 of the Code results from a transaction or series of transactions over a three year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain shareholders. As of December 31, 2016 and December 31, 2015, the Company does not have any unrecognized tax benefits. The Company does not anticipate a significant increase in the unrecognized tax benefits over the next 12 months. The Companys policy is to recognize interest expense and penalties related to income matters as a component of the income tax provision. As of December 31, 2016 and December 31, 2015, the Company did not have any tax related accrued interest and penalties on its balance sheet or on its statement of operations.

Legal Proceedings

Legal Proceedings	12 Months Ended
	Dec. 31, 2016
Legal Proceedings
Legal Proceedings	Note 9 – Legal Proceedings From time to time, claims are made against us in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from selling one or more products or engaging in other activities. The occurrence of an unfavorable outcome in any specific period could have a material adverse effect on our results of operations for that period or future periods. However, as of the date of this report, management believes the outcome of currently identified potential claims and lawsuits will not have a material adverse effect on our financial condition or results of operations.

Discontinued Operation

Discontinued Operation	12 Months Ended
	Dec. 31, 2016
Discontinued Operation:
Discontinued Operation	Note 10 – Discontinued Operation The following are the summarized results of discontinued operations for the years ended December 31, 2016 and 2015. For the Year Ended December 31, 2016 For the Year Ended December 31, 2015 Bad debt $ - $ (9,770) Obsolete Inventory - (4,052) $ - $ (13,822)

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2016
Subsequent Events:
Subsequent Events	Note 11 – Subsequent Events On January 17, 2017, we issued 12,500,000 shares of common stock, valued at $0.004 per share, for an investment in the Company’s Private Placement to a related party. On March 2, 2017, we issued 12,500,000 shares of common stock, valued at $0.004 per share, for an investment in the Company’s Private Placement to a related party. On April 3, 2017, we issued 1,000,000 shares of common stock, valued at $.0067 per share for consulting services. On April 20, 2017, we issued a six month convertible note in the amount of $100,000 with an annual interest rate of 10% to a related party. On May 8, 2017, we issued 10,000,000 shares of common stock, valued at $.008 per share, for legal services and 1, 0 00,000 shares of common stock, valued at $0.004 per share, for an investment in the Company’s Private Placement.

Accounting Policies (Policies)

Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies:
Use of Estimates	Use of Estimates Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates.
Comprehensive Loss	Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Company’s net loss.
Net Loss Per Share	Net Loss Per Share Basic net loss per share is calculated based on the weighted-average number of common shares outstanding. Diluted net loss per share is calculated using the weighted-average number of common shares outstanding plus common stock equivalents. Common stock equivalents are excluded from the calculation of diluted net loss per share when their effect is anti-dilutive. As of December 31, 2016 and 2015, common stock equivalents were not material.
Depreciation and Amortization, Policy	Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement.
Intangible Assets, Policy	Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with Accounting Standards Codification (“ASC”) Topic 350 “Intangibles – Goodwill and Other.”
Long-lived Assets	Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value.
Income Taxes, Policy	Income Taxes The Company accounts for income taxes under ASC 740 "Income Taxes," which codified SFAS 109, "Accounting for Income Taxes" and FIN 48 “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to
Stock-Based Compensation	Stock-Based Compensation Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 will be effective for the Company in the first quarter of 2019 and will be adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company is currently evaluating the impact of this standard on its consolidated financial statements. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The new standard requires management to assess, at each annual and interim reporting period, an entity’s ability to continue as a going concern within one year after the date that the financial statements are issued and to provide related footnote disclosures. ASU 2014-15 is effective for the Company for the year ending December 31, 2016. Based on its adoption of ASU 2014-15, management determined that there is substantial doubt regarding the company’s ability to continue as a growing concern within one year after the issuance of the financial statements (see Note 1). In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The new standard is based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 will be effective for the Company in the first quarter of 2018 and allows for full retrospective or a modified retrospective adoption approach. The adoption of this standard is not expected to have a material impact on the Company’s financial position or results of operations

Fixed assets (Tables)

Fixed assets (Tables)	12 Months Ended
	Dec. 31, 2016
Fixed assets (Tables):
Fixed assets (Tables)	Fixed assets consist of the following: December 31, 2016 December 31, 2015 Computer Hardware $ 10,747 $ 10,747 Office Furniture and Equipment 3,639 3,639 Shipping and Other Equipment 1,575 1,575 Total 15,961 15,961 Accumulated Depreciation (15,961) (15,961) Property and Equipment, net $ - $ -

Schedule of Notes Payable-relat

Schedule of Notes Payable-related party (Tables)	12 Months Ended
	Dec. 31, 2016
Schedule of Notes Payable-related party
Schedule of Notes Payable-related party	Notes payable-related parties consist of: December 31, December 31, 2016 2015 Note payable – Scientific Advisory Board Member, unsecured, including interest at 10% per annum, with a maturity date of December 31, 2017 $ 14,721 $ 13,574 Three notes payable – Chief Executive Officer, unsecured, including interest at 8%, 10% and 10% per annum, respectively, with maturity dates of December 31, 2017. 120,330 113,664 Note payable – Chief Financial Officer, unsecured, including interest at 8% per annum, with a maturity date of December 31, 2017. 86,400 80,000 221,451 207,238 Note payable – Business Advisory Board Member, unsecured, including interest at 8% per annum, convertible into common stock at $.005, with a maturity date of May 29, 2018. 75,500 - $ 296,951 $ 207,238

Schedule of Income Taxes (Table

Schedule of Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Schedule of Income Taxes
Schedule of Effective Income Tax Rate Reconciliation	The reconciliation of the provision for income taxes at the United States federal statutory rate compared to the Company’s income tax expense as reported is as follows: December 31, 2016 December 31, 2015 Expected income tax at statutory rate $ (360,963) $ (263,898) Permanent differences 1,437 88,616 Change in valuation allowance 359,526 175,282 Provision for income taxes $ – $ –
Schedule of Deferred Tax Assets and Liabilities	The significant components of deferred income tax assets and liabilities at December 31, 2016 and 2015 are as follows: December 31, 2016 December 31, 2015 Net operating loss carry-forward $ 1,262,691 $ 1,021,679 Valuation allowance (1,262,691) (1,021,679) Net deferred income tax asset $ – $ –

Schedule of Summary of Results

Schedule of Summary of Results of Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2016
Schedule of Summary of Results of Discontinued Operations
Schedule of Summary of Results of Discontinued Operations	The following are the summarized results of discontinued operations for the years ended December 31, 2016 and 2015. For the Year Ended December 31, 2016 For the Year Ended December 31, 2015 Bad debt $ - $ (9,770) Obsolete Inventory - (4,052) $ - $ (13,822)

Nature of Business (Details)

Nature of Business (Details)	Dec. 31, 2016USD ($)
Nature of Business Details
Accumulated deficits	$ 4,273
Working capital deficit	$ 612

Restricted Cash (Details)

Restricted Cash (Details)	Dec. 31, 2016USD ($)
Restricted Cash Details
Other non-current asset certificate of deposit	$ 10,000
Annual interest rate	0.60%

Fixed assets (Details)

Fixed assets (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Fixed assets Consists Of the Following:
Computer Hardware	$ 10,747	$ 10,747
Office Furniture and Equipment	3,639	3,639
Shipping and Other Equipment	1,575	1,575
Total Fixed assets	15,961	15,961
Accumulated Depreciation	(15,961)	(15,961)
Property and Equipment, net	$ 0	$ 0

Notes Payable-Related Parties (

Notes Payable-Related Parties (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Notes Payable-Related Parties Details
Note payable - Scientific Advisory Board	$ 14,721	$ 13,574
Three notes payable - Chief Executive Officer	120,330	113,664
Note payable - Chief Financial Officer	86,400	80,000
Total Note payable	221,451	207,238
Note payable - Business Advisory Board	75,500	0
Total Notes Payable-Related Parties	$ 296,951	$ 207,238

Capital Stock Transactions (Det

Capital Stock Transactions (Details)	Dec. 31, 2016$ / sharesshares
PREFERRED STOCK:
Preferred Stock, authorized shares | shares	5,000,000
Preferred Stock par value | $ / shares	$ 0.001

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	Dec. 31, 2016	Nov. 11, 2016	Oct. 18, 2016	Sep. 16, 2016	Mar. 21, 2016	Mar. 07, 2016	Feb. 26, 2016	Jan. 22, 2016
Related Party Transactions Details
Issued shares of common stock for consulting services						10,000,000		2,500,000
Issued shares of common stockfor consulting services per share						$ 0.0025		$ 0.0035
Issued shares of common stock for for an investment in Private Placement				12,500,000	100,800,000		1,000,000
Issued shares of common stock for an investment in Private Placement per share				$ 0.004	$ 0.0025		$ 0.0025
Issued shares of common stock to the officers and directors			40,000,000
Issued shares of common stock to the officers and directors per share			$ 0.0045
Issued shares of common stock for for an investment in Private Placement					10,000,000
Issued shares of common stock for an investment in Private Placement per share					$ 0.0025
Issued convertible note		$ 75,000
Convertible note with an annual interest rate		8.00%
Company accrued officers salary	$ 130,100

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Income Taxes Narrative Details
Net operating losses carried forward	$ 3,300,000	$ 2,300,000

Income tax expense as reported

Income tax expense as reported is as follows (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Income tax expense as reported is as follows details
Expected income tax at statutory rate	$ (360,963)	$ (263,898)
Permanent differences	1,437	88,616
Change in valuation allowance	359,526	$ 175,282
Provision for income taxes	$ 0

Components of deferred income t

Components of deferred income tax assets and liabilities (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Components of deferred income tax assets and liabilities:
Net operating loss carry-forward	$ 1,262,691	$ 1,021,679
Valuation allowance	(1,262,691)	$ (1,021,679)
Net deferred income tax asset	$ 0

Results of discontinued operati

Results of discontinued operations (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Results of discontinued operations details
Discontinued operations Bad debt		$ (9,770)
Discontinued operations Obsolete Inventory		(4,052)
Total assets of discontinued operations	$ 0	$ (13,822)

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	May 08, 2017	Apr. 20, 2017	Apr. 03, 2017	Mar. 02, 2017	Jan. 17, 2017
Subsequent Events Details
Issued shares of common stock for an investment in Private Placement to a related party	10,000,000			12,500,000	12,500,000
Issued shares of common stock for an investment in Private Placement to a related party per share	$ 0.004			$ 0.004	$ 0.004
Issued shares of common stock for consulting services			1,000,000
Issued shares of common stock for consulting services per share			$ 0.0067
Issued convertible note to a related party		$ 100,000
Convertible note to a related party with an annual interest rate		10.00%
Issued shares of common stock for legal services	10,000,000
Issued shares of common stock for legal services per share	$ 0.008

Uncategorized Items - tsoi-2016

Label	Element	Value
Cash at beginning of period	us-gaap_CashAndCashEquivalentsAtCarryingValue	$ 2,894